My Dashboard
Fin. Planning
Our Solutions
Stocks
Funds
Invest in the best stock opportunities right now and every time.
Start Systematic Stock Investing …in less than a minute.
BSE: 512529 | NSE: SEQUENT | Pharmaceuticals & Drugs | Small Cap
1. Is Sequent Scientific Ltd a good quality company?
Past 10 year's financial track record analysis by Moneyworks4me indicates that Sequent Scientific Ltd is a average quality company.
2. Is Sequent Scientific Ltd undervalued or overvalued?
The key valuation ratios of Sequent Scientific Ltd's currently when compared to its past seem to suggest it is in the Fair zone.
3. Is Sequent Scientific Ltd a good buy now?
The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Sequent Scientific Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
Value Creation ⓘValue Creation Index Colour Code Guide ⓘ |
|||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar'13 | Mar'14 | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | TTM | |||
| ROCE % ⓘ | -9% | -8.3% | -1.1% | 0.7% | 1.2% | 13.8% | 7.4% | 9.2% | 11.5% | 4.6% | - | ||
| Value Creation Index ⓘ | -1.6 | -1.6 | -1.1 | -1.0 | -0.9 | -0.0 | -0.5 | -0.4 | -0.2 | -0.7 | - | ||
Growth Parameters ⓘGrowth Parameters Colour Code Guide ⓘ |
|||||||||||||
| Sales ⓘ | 327 | 455 | 465 | 625 | 684 | 1,031 | 1,039 | 1,179 | 1,362 | 1,413 | 1,421 | ||
| YoY Gr. Rt. % | - | 39.4% | 2.2% | 34.3% | 9.4% | 50.8% | 0.9% | 13.5% | 15.5% | 3.8% | - | ||
| Adj EPS ⓘ | -5 | -4.7 | -2.5 | -0.9 | -0.2 | 5.7 | 2.2 | 3 | 4.1 | 1.5 | 0.3 | ||
| YoY Gr. Rt. % | - | NA | NA | NA | NA | NA | -61.7% | 36.4% | 39.2% | -64.1% | - | ||
| BVPS (₹) ⓘ | 7.1 | 2 | 3.8 | 38.7 | 39.4 | 25.9 | 27.9 | 27.1 | 29 | 26 | 29.6 | ||
| Adj Net Profit ⓘ | -59.5 | -64.2 | -37.8 | -20.5 | -4.1 | 138 | 53.6 | 73.4 | 102 | 36.7 | 8 | ||
| Cash Flow from Ops. ⓘ | -3.8 | -44.8 | -23.6 | -0.1 | -7.2 | 45.2 | 116 | 115 | 115 | 30.6 | - | ||
| Debt/CF from Ops. ⓘ | -81.5 | -9.3 | -20.1 | -5782.5 | -57.8 | 6.7 | 2.8 | 3 | 2 | 10.3 | - | ||
CAGR ⓘCAGR Colour Code Guide ⓘ |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 9 Years | 5 Years | 3 Years | 1 Years | |||||||||
| Sales ⓘ | 17.7% | 15.6% | 10.8% | 3.8% | ||||||||
| Adj EPS ⓘ | NA | NA | -12% | -64.1% | ||||||||
| BVPS ⓘ | 15.5 | -8 | -2.3 | -10.4 | ||||||||
| Share Price | 9.7% | -1.1% | 11% | -41.4% | ||||||||
Key Financial Parameters ⓘPerformance Ratio Colour Code Guide ⓘ |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar'13 | Mar'14 | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | TTM | ||
| Return on Equity % ⓘ | -54.7 | -84.6 | -51.1 | -4 | -0.4 | 17 | 7.9 | 10.5 | 14.5 | 5.2 | 1.2 | |
| Op. Profit Mgn % ⓘ | -2.4 | 5.7 | 4.7 | 9.5 | 8.1 | 11.2 | 12.8 | 14.9 | 15.7 | 7.8 | 5.3 | |
| Net Profit Mgn % ⓘ | -18.2 | -14.1 | -8.4 | -3 | -1 | 14.3 | 6 | 7.3 | 8.2 | 2.9 | 0.6 | |
| Debt to Equity ⓘ | 3.7 | 15.9 | 8.3 | 0.3 | 0.4 | 0.5 | 0.5 | 0.5 | 0.3 | 0.5 | 0.2 | |
| Working Cap Days ⓘ | 251 | 210 | 233 | 224 | 314 | 226 | 206 | 190 | 183 | 200 | 205 | |
| Cash Conv. Cycle ⓘ | 6 | 13 | 61 | 76 | 93 | 70 | 79 | 73 | 83 | 98 | 72 | |
Sales growth is growing at healthy rate in last 3 years 10.78%
Return on Equity has declined versus last 3 years average to 1.20%
Net Profit has been subdued in last 3 years -11.98%
Sales growth is not so good in last 4 quarters at 2.42%
| Standalone | Consolidated | |
|---|---|---|
| TTM EPS (₹) | 0.3 | 0.3 |
| TTM Sales (₹ Cr.) | 242 | 1,421 |
| BVPS (₹.) ⓘ | 41.9 | 29.6 |
| Reserves (₹ Cr.) ⓘ | 995 | 688 |
| P/BV ⓘ | 2.26 | 3.20 |
| PE ⓘ | 298.27 | 285.12 |
| From the Market | |
|---|---|
| 52 Week Low / High (₹) | 81.40 / 204.45 |
| All Time Low / High (₹) | 0.40 / 336.40 |
| Market Cap (₹ Cr.) | 2,360 |
| Equity (₹ Cr.) | 49.9 |
| Face Value (₹) | 2 |
| Industry PE ⓘ | 37.8 |
| Pledged * | 44.60 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
P I Drugs & Pharmaceuticals Ltd. established in 1991 is a leading manufacturer, exporter of specialized quality formulations having an objective of fulfilling the diverse demands of pharmaceutical industry.
P I Drugs & Pharmaceuticals Ltd. specializes in the manufacturing of the formulation belonging to anthelmintic & anti-parasitic segment.
In September 2007 PI Drugs purchased the pharma division of Transchem Limited.
The company is engaged in the business of human health & animal health and enjoys high Image for distribution in domestic as well as international markets.
They have a specialized and dedicated WHO - GMP accredited manufacturing plant for the manufacture of API's. It exports to all major markets like Europe, South America, Australia, Asia and Africa.
They started with the introduction of Albendazole and has developed core competency in chemistry of Benzimadazole in very short time.
Product range of the company includes:
Human / Veterinary Formulations
Honey Bee Medicine
Human / Veterinary API's
Veterinary API’s
Human API's
